Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TXG 
10X Genomics Inc (TXG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TXG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $13.08
Year Target Price $13.08
| 5 | Strong Buy |
| 2 | Buy |
| 9 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.99% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.43B USD | Price to earnings Ratio - | 1Y Target Price 13.08 |
Price to earnings Ratio - | 1Y Target Price 13.08 | ||
Volume (30-day avg) 16 | Beta 1.98 | 52 Weeks Range 6.78 - 24.76 | Updated Date 07/1/2025 |
52 Weeks Range 6.78 - 24.76 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -25.14% | Operating Margin (TTM) -31.33% |
Management Effectiveness
Return on Assets (TTM) -12.43% | Return on Equity (TTM) -22.03% |
Valuation
Trailing PE - | Forward PE 196.08 | Enterprise Value 1078442156 | Price to Sales(TTM) 2.28 |
Enterprise Value 1078442156 | Price to Sales(TTM) 2.28 | ||
Enterprise Value to Revenue 1.73 | Enterprise Value to EBITDA -40.69 | Shares Outstanding 111093000 | Shares Floating 109010309 |
Shares Outstanding 111093000 | Shares Floating 109010309 | ||
Percent Insiders 1.93 | Percent Institutions 102.33 |
Analyst Ratings
Rating 4 | Target Price 13.08 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold 9 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
10X Genomics Inc
Company Overview
History and Background
10X Genomics was founded in 2012. It focuses on developing and manufacturing instruments, consumables, and software for analyzing biological systems. The company went public in 2019.
Core Business Areas
- Genomics: Developing tools for single-cell gene expression, single-cell immune profiling, and other genomics applications.
- Spatial Biology: Provides solutions for spatially resolved transcriptomics and proteomics, allowing researchers to understand biological processes in the context of tissue architecture.
- Software: Offers software suites to analyze and visualize data generated by its instruments, making complex genomic information more accessible.
Leadership and Structure
Serge Saxonov is the CEO. The company has a typical corporate structure with departments focused on R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- Chromium Solutions: These microfluidics-based instruments and reagents enable single-cell gene expression analysis. The Chromium X Series is used in a wide range of Genomics. Competitors include Bio-Rad (BIO), Illumina (ILMN), and BD Biosciences (BDX).
- Visium Spatial Solutions: This technology enables spatial transcriptomics, providing gene expression information in the context of tissue architecture. Competitors include Akoya Biosciences (AKYA) and NanoString Technologies (NSTG).
- Xenium In Situ: Enables high-plex in situ analysis at subcellular resolution. Competitors include NanoString Technologies (NSTG) and Vizgen.
Market Dynamics
Industry Overview
The genomics and spatial biology market is rapidly growing due to increasing demand for personalized medicine and advanced research tools. Key trends include single-cell analysis, spatial transcriptomics, and multiomics approaches.
Positioning
10X Genomics is a leading player in the genomics and spatial biology market, known for its innovative technologies and comprehensive solutions. It holds a strong market share in single-cell sequencing and is expanding its presence in spatial transcriptomics.
Total Addressable Market (TAM)
The estimated TAM for single-cell and spatial biology is tens of billions of dollars. 10X Genomics is well-positioned to capture a significant portion of this market with its expanding product portfolio and leading market position.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong market position
- Comprehensive solutions
- Large and growing customer base
- Extensive IP portfolio
Weaknesses
- High product cost
- Reliance on a few key products
- Competition from larger players
- Ongoing patent litigation
Opportunities
- Expanding into new markets
- Developing new applications for existing technologies
- Acquiring complementary technologies
- Partnering with pharmaceutical companies
Threats
- Intense competition
- Technological obsolescence
- Patent challenges
- Economic downturn
- Reimbursement risk
Competitors and Market Share
Key Competitors
- ILMN
- BIO
- AKYA
- NSTG
Competitive Landscape
10X Genomics faces competition from established players like Illumina and Bio-Rad, as well as emerging companies like Akoya Biosciences and NanoString Technologies. 10X Genomics' strength lies in its innovative technology and comprehensive solutions. However, its high product cost and reliance on a few key products are potential weaknesses.
Major Acquisitions
ReadCoor
- Year: 2020
- Acquisition Price (USD millions): 350
- Strategic Rationale: Strengthened its position in spatial genomics by adding multiplexed fluorescence in situ hybridization (FISH) capabilities.
Growth Trajectory and Initiatives
Historical Growth: 10X Genomics experienced rapid revenue growth in its early years as a public company. Growth has slowed recently due to increased competition and macroeconomic factors.
Future Projections: Analysts expect 10X Genomics to resume strong growth in the coming years as it expands its product portfolio and penetrates new markets. Revenue growth is projected to be in the double digits.
Recent Initiatives: Recent strategic initiatives include the launch of new products (Xenium In Situ), expansion into spatial biology, and partnerships with pharmaceutical companies.
Summary
10X Genomics is a key player in the expanding genomics and spatial biology market, known for innovative technologies. It possesses strengths in its proprietary products and market positioning. Key things to look out for are intense competition, product cost, and patent challenges. Its strong cash reserves support future growth initiatives.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Press releases
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. The AI-based rating is subjective and should be used as one factor among many when making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 10X Genomics Inc
Exchange NASDAQ | Headquaters Pleasanton, CA, United States | ||
IPO Launch date 2019-09-12 | Co-Founder, CEO & Director Dr. Serge Saxonov Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 1306 | Website https://www.10xgenomics.com |
Full time employees 1306 | Website https://www.10xgenomics.com | ||
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.